Heim, Payne & Chorush Helps Lipitor® Buyers Win Court Approval for $93 Million Antitrust Settlement
Heim, Payne & Chorush, LLP, recently helped a group of clients win court approval for a settlement requiring multinational pharmaceutical company Pfizer Inc. to pay $93 million for delaying a cheaper generic version of its popular cholesterol medication Lipitor®.
Heim, Payne & Chorush partners Russell Chorush, Blaine Larson, and Allan Bullwinkel, and associates Carlos Ruiz, Kyle Ruvolo, and Michael Dunbar worked with other law firms nationwide to secure the settlement that was announced earlier this year in Lipitor Antitrust Litigation, No. 3:12-cv-02389, U.S. District Court for the District of New Jersey.
The June 12, 2024, order includes $31 million in attorneys’ fees that will be divided among Heim, Payne & Chorush and other firms representing the Lipitor® purchasers, who sued Pfizer for paying a drug manufacturer to delay its generic version of the medication. The settlement covers the plaintiffs who bought Lipitor ® from June 2011 through May 2012.
Dr. Chorush and Heim, Payne & Chorush represent businesses from various industries in claims brought under the Sherman Antitrust Act and the Supreme Court’s decision in FTC v. Actavis, Inc. In addition to the Lipitor® litigation, the firm actively represents or has previously represented direct purchasers in cases involving the pharmaceutical drug products Namenda®, Provigil®, Tricor®, Neurontin®, Buspar®, K-Dur®, Aggrenox®, Lidoderm®, Neurontin ®, Colcrys®, Bystolic®, Seroquel XR ®, Niaspan®, and AndroGel®.